Skip to main content

Table 1 Participant characteristics and types of PIEDs used prior to lockdown

From: Investigating the impact of COVID-19 on performance and image enhancing drug use

  Sample Blast-Cruise OR[t] 95% CI p value
  (n = 60) No (n = 17) Yes (n = 43)
Mean age 26.69 27.56 26.37 [.616] - n.s
Mean BMI 26.20 25.27 26.20 [1.779] - n.s
Mean percentage body fat 15.00 15.60 15.13 .119 -0.5,0.6 n.s
Competed in a bodybuilding show (%) 11.7 94.5 86.7 0.4 0.1,3.5 n.s
Heterosexual (%) 95.0 94.5 95.4 1.3 0.1,15.1 n.s
Injectable (%; n)
 Testosterone 70; 42 47.1 79.1 4.3 1.3,14.2 0.007
 Trenbolone 28.3; 17 5.9 37.2 9.5 1.1,78.4 0.007
 Boldenone 23.3; 14 11.8 27.9 2.9 0.5,14.7 n.s
 Drostanolone 16.7; 10 5.9 20.9 4.2 0.5,36.4 n.s
 Stanazolol 13.3; 8 6.3 14.0 2.6 0.3,23.3 n.s
 Nandrolone 13.3; 8 11.8 16.3 1.5 0.3,7.8 n.s
 Methenolone 5; 3 11.8 2.3 0.2 0.1,2.1 n.s
Oral (%; n)
 Oxandrolone 28.3; 17 17.6 32.6 2.3 0.6,9.1 n.s
 Metandienone 25; 15 17.6 27.9 1.8 0.4,7.4 n.s
 Oxymetholone 13.3; 8 5.9 16.3 3.1 0.4,27.4 n.s
 Stanazolol 11.7; 7 5.9 16.3 3.1 .4,27.4 n.s
 Mesterolone 8.3; 5 5.9 9.3 1.6 0.2,15.8 n.s
 Chlorodehydromethyltestosterone 1.7; 1 5.9 0.0 0.3 0.2,0.4 n.s
 Fluoxymesterone 1.7; 1 0.0 2.3 0.7 0.6,0.8 n.s
Other PIEDs (%; n)
 Clenbuterol 16.7; 10 5.9 20.9 4.2 0.5,36.4 n.s
 Human-growth-hormone 10; 6 5.9 11.6 2.1 0.2,19.5 n.s
 Peptides 10; 6 11.8 9.3 0.8 0.1,4.6 n.s
 Insulin 8.3; 5 5.9 9.3 1.6 0.2,15.8 n.s
 Prohormones 8.3; 5 0.0 11.6 0.7 0.6,0.8 n.s
 Selective-androgen-receptor-modulators 6.7; 4 5.9 7.0 1.2 0.1,12.4 n.s
 T3 5; 3 5.9 4.7 0.8 0.1,9.2 n.s
 Insulin-like-growth-factor-1 5; 3 5.9 4.7 0.8 0.1,9.2 n.s
  1. Specific p values available from authors on request